Fibrosis
From Pepperpedia, the free peptide encyclopedia
Fibrosis
Properties
| Category | Glossary |
|---|---|
| Also known as | Fibrotic Tissue, Scar Formation, Tissue Fibrosis |
| Last updated | 2026-04-13 |
| Reading time | 4 min read |
| Tags | pathologytissue repaircollagenglossary |
Overview
Fibrosis is the formation of excess fibrous connective tissue in a tissue or organ, typically as a consequence of chronic injury, persistent inflammation, or dysregulated repair processes. The hallmark of fibrosis is the excessive deposition of collagen and other extracellular matrix (ECM) components by activated fibroblasts, often called myofibroblasts.
While normal wound healing involves a controlled phase of matrix deposition followed by remodeling, fibrosis occurs when this process fails to resolve. The result is stiff, scarred tissue that can progressively impair organ function. Fibrosis can affect virtually any organ, including the liver (cirrhosis), lungs (pulmonary fibrosis), kidneys, heart, and skin (keloids and hypertrophic scars).
Detailed Explanation
Pathophysiology
The fibrotic process generally follows a sequence:
- Tissue injury — Damage from infection, toxins, autoimmune attack, mechanical stress, or ischemia triggers an inflammatory response.
- Inflammatory phase — Immune cells (macrophages, neutrophils, lymphocytes) infiltrate the tissue and release pro-inflammatory cytokines and growth factors.
- Fibroblast activation — Resident fibroblasts are activated by signals such as TGF-beta, PDGF, and IL-13. They differentiate into myofibroblasts, which produce large quantities of collagen and other ECM proteins.
- Matrix accumulation — If the injurious stimulus persists or the repair process is dysregulated, ECM deposition outpaces degradation. The normal tissue architecture is progressively replaced by dense fibrous tissue.
- Failed resolution — In normal healing, myofibroblasts undergo apoptosis and excess matrix is remodeled. In fibrosis, these resolution mechanisms fail.
Key Mediators
- TGF-beta (transforming growth factor beta) — The principal pro-fibrotic cytokine. It drives fibroblast-to-myofibroblast conversion and stimulates collagen synthesis.
- PDGF (platelet-derived growth factor) — Promotes fibroblast proliferation and migration.
- Connective tissue growth factor (CTGF) — Amplifies TGF-beta signaling and promotes ECM production.
- Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) — The balance between MMPs (which degrade matrix) and TIMPs (which inhibit MMPs) determines whether matrix accumulates or is remodeled.
Functional Consequences
Fibrotic tissue is characterized by:
- Increased stiffness and reduced compliance
- Loss of normal tissue architecture
- Impaired organ function (e.g., reduced gas exchange in pulmonary fibrosis, impaired filtration in renal fibrosis)
- Potential progression to organ failure if unchecked
Relevance to Peptide Research
Fibrosis is a major focus of peptide research for several reasons:
- Anti-fibrotic peptides — Several research peptides are investigated for their potential to modulate fibrotic pathways. BPC-157 has been studied in animal models for its effects on wound healing and tissue remodeling, including fibrotic outcomes.
- Collagen modulation — Peptides that influence collagen synthesis or degradation are relevant to fibrosis research, as the net balance of collagen production and breakdown determines fibrotic progression or resolution.
- Biomarker assessment — Peptide fragments released during collagen turnover (e.g., procollagen type III N-terminal peptide, P3NP) serve as serum biomarkers for fibrotic activity.
- Signaling pathway targets — Research peptides that modulate TGF-beta signaling, MMP activity, or myofibroblast behavior are studied in the context of fibrosis.
Examples
- Chronic liver inflammation from sustained hepatotoxic exposure leads to progressive collagen deposition, replacing functional hepatocytes with fibrotic tissue (hepatic fibrosis progressing toward cirrhosis).
- In a rodent model of pulmonary fibrosis induced by bleomycin, researchers measure hydroxyproline content (a collagen-specific amino acid) as a quantitative index of fibrotic severity.
- A peptide is evaluated for its ability to reduce TGF-beta-stimulated collagen production in cultured myofibroblasts as a preliminary screen for anti-fibrotic potential.
Related Terms
- Collagen — The primary structural protein deposited in fibrotic tissue
- Extracellular Matrix — The structural scaffold that accumulates in fibrosis
- Cytokine — Signaling molecules such as TGF-beta that drive fibrotic processes
- Angiogenesis — New blood vessel formation that accompanies tissue remodeling
- Paracrine Signaling — The local signaling mode through which pro-fibrotic factors operate
Related entries
- Angiogenesis— The physiological process of forming new blood vessels from pre-existing vasculature, essential for tissue repair, wound healing, and a key target in peptide research.
- Collagen— The most abundant structural protein in the human body, forming a triple-helix architecture that provides tensile strength to connective tissues including skin, tendons, bone, and cartilage.
- Cytokine— A broad category of small signaling proteins secreted by cells of the immune system that mediate and regulate inflammation, immunity, and hematopoiesis — key targets and modulators in peptide research.
- Extracellular Matrix— The complex network of proteins, glycoproteins, and polysaccharides secreted by cells that provides structural support, biochemical signaling, and a physical scaffold for tissue organization.
- Paracrine Signaling— A mode of cell signaling in which a cell secretes molecules that act on nearby target cells, traveling short distances through the extracellular space without entering the systemic circulation.